Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19
Background The coronavirus disease 2019 (COVID‐19) pandemic has resulted in
substantial mortality. Some specialists proposed chloroquine (CQ) and hydroxychloroquine …
substantial mortality. Some specialists proposed chloroquine (CQ) and hydroxychloroquine …
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
Background Numerous clinical trials and observational studies have investigated various
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19) …
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19) …
Prophylaxis against covid-19: living systematic review and network meta-analysis
Updates This is the second version (first update) of the living systematic review, replacing
the previous version (available as a data supplement). When citing this paper please …
the previous version (available as a data supplement). When citing this paper please …
Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
S Juul, EE Nielsen, J Feinberg, F Siddiqui… - PLoS …, 2020 - journals.plos.org
Background Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has
caused extensive burden to individuals, families, countries, and the world. Effective …
caused extensive burden to individuals, families, countries, and the world. Effective …
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019
Hydroxychloroquine, initially used as an antimalarial, is used as an immunomodulatory and
anti-inflammatory agent for the management of autoimmune and rheumatic diseases such …
anti-inflammatory agent for the management of autoimmune and rheumatic diseases such …
[HTML][HTML] Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China,
in December 2020 and coronavirus disease 19 (COVID-19) was later announced as …
in December 2020 and coronavirus disease 19 (COVID-19) was later announced as …
[HTML][HTML] Kidney injury in COVID-19 patients, drug development and their renal complications: Review study
ZM Yarijani, H Najafi - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Since December 2019, the world was encountered a new disease called coronavirus
disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 …
disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 …
[HTML][HTML] Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), accountable for causing
the coronavirus diseases 2019 (COVID-19), is already declared as a pandemic disease …
the coronavirus diseases 2019 (COVID-19), is already declared as a pandemic disease …
Deciphering SARS-CoV-2 virologic and immunologic features
G Lebeau, D Vagner, E Frumence, F Ah-Pine… - International journal of …, 2020 - mdpi.com
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated
pathology, COVID-19, have been of particular concerns these last months due to the …
pathology, COVID-19, have been of particular concerns these last months due to the …
[HTML][HTML] Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized …
Abstract The coronavirus disease 19 (COVID-19) pandemic has caused significant morbidity
and mortality worldwide and an effective treatment is needed. Chloroquine (CQ) and …
and mortality worldwide and an effective treatment is needed. Chloroquine (CQ) and …